Ganymed Pharmaceuticals AG
Freiligrathstrasse 12
Mainz
D-55131
Germany
Tel: 49-0-6131-1440-10
Fax: 49-0-6131-1440-111
19 articles about Ganymed Pharmaceuticals AG
-
Astellas Completes Acquisition Of Ganymed
12/21/2016
-
Little-Known Ganymed Grabs a $1.4 Billion Buyout Deal From Astellas
10/31/2016
-
ASCO2016: GANYMED Pharmaceuticals AG's IMAB362 Extends Survival In Gastric Cancer
6/6/2016
-
GANYMED Pharmaceuticals AG To Present Exciting Phase II Clinical Data For IMAB362 In Gastroesophageal Cancer At ASCO 2016 Annual Meeting
5/17/2016
-
BioNTech AG GANYMED Pharmaceuticals AG Open New Research Headquarters In Mainz, Germany
10/1/2014
-
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer
7/22/2014
-
GANYMED Pharmaceuticals AG's IMAB362 Shows Strong Evidence Of Single-Agent Activity In Phase 2a Trial In Gastroesophageal Cancer
5/27/2014
-
GANYMED Pharmaceuticals AG's IMAB027 Enters Phase I/II Clinical Trial For Ovarian Cancer
2/12/2014
-
GANYMED Pharmaceuticals AG To Present At The 32nd Annual J.P. Morgan Healthcare Conference
12/19/2013
-
GANYMED Pharmaceuticals AG Scrounges Up $60 Million Financing Round
11/18/2013
-
GANYMED Pharmaceuticals AG's IMAB362 Receives Orphan Drug Designation From FDA and European Medicines Agency for Pancreatic Cancer
10/21/2013
-
GANYMED Pharmaceuticals AG Announces CE Marking for Test to Assess Claudin-18.2 Expression in Solid Tumors
9/11/2013
-
GANYMED Pharmaceuticals AG Release: Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety
8/4/2010
-
GANYMED Pharmaceuticals AG Closes EUR 65 M Financing Round
11/18/2008
-
ATS Acquires Majority Shareholding in GANYMED Pharmaceuticals AG
8/21/2008
-
Selexis SA Signs Commercial License Agreement With GANYMED Pharmaceuticals AG
7/11/2007
-
GANYMED Pharmaceuticals AG Raises Euro 33.7 Million in Series C Financing Round
4/18/2007
-
Dr. Thomas M. Rinderknecht Chairs Supervisory Board Of GANYMED Pharmaceuticals AG
10/11/2006
-
GANYMED Pharmaceuticals AG Lead Antibodies Show Excellent Efficacy And Safety In Mouse Tumor Models
4/5/2006